Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Effectiveness, Acceptability and Feasibility of a Communication and Care Coordinator (CCC) Model in Facilitating Serious Illness Communication (SIC) and Care in Patients With Cancer (CCC-Cancer)

5 de noviembre de 2026 actualizado por: National Cancer Centre, Singapore

Evaluating the Effectiveness, Acceptability and Feasibility of a Communication and Care Coordinator (CCC) Model in Facilitating Serious Illness Communication (SIC) and Care in Patients With Cancer

The goal of this clinical trial is to evaluate the communication and care coordinator (CCC) model in a national cancer institute and assess the utility of the model in facilitating serious illness communication (SIC) and care for patients with cancer.

The study aims are:

  • To assess the effectiveness of the CCC model in improving patient outcomes.
  • To assess the effectiveness of the CCC model in increasing rates of SIC and advance care planning (ACP) record documentation.
  • To assess the acceptability of the CCC model to patients and clinicians.
  • To evaluate the feasibility of implementing a CCC model in oncology care.

Researchers will compare results from the CCC intervention arm and usual care arm, to see if the CCC model can help improve patient outcomes and facilitate SIC between patients and clinicians.

Patient participants will:

  • Follow the assignment of their clinician, who will be assigned randomly to either the usual care group or the intervention group.
  • Be assigned a CCC and receive 6 CCC sessions over the course of 3 months (if assigned to CCC intervention arm).
  • Complete 3 study assessment visits at baseline, Week 6, and 3 months
  • Be invited to a one-time interview to share their study experience (optional, if selected and if in CCC intervention arm).

Descripción general del estudio

Estado

Reclutamiento

Condiciones

Intervención / Tratamiento

Descripción detallada

Timely SIC may facilitate earlier preferred plan of care documentation and improve patients' sense of peacefulness, hopefulness, and connectedness with their clinicians. The primary goal of the study is to evaluate the CCC model in a national cancer institute and assess the utility of the model in facilitating SIC and care for patients with cancer through a stepped wedge cluster randomized trial. This approach delivers crucial, empirical insights into how SIC can be efficiently and effectively delivered and potentially allow larger scale implementation and dissemination of the CCC model in Singapore, as an effective model for delivering patient support and facilitating patient-clinician communication in patients with advanced cancer.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

560

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Copia de seguridad de contactos de estudio

  • Nombre: Benton PT TAM, MSc

Ubicaciones de estudio

      • Singapore, Singapur, 168583
        • Reclutamiento
        • National Cancer Center, Singapore
        • Contacto:
          • Shirlyn NEO Hui Shan, MD, PhD
        • Contacto:

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

21 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

Patient Participants

  • Aged 21 and above
  • Diagnosed with (a) advanced cancer (stage 3 or 4) or (b) non-advanced cancer, but at high risk of recurrence
  • Able to speak English or Chinese, irrespective of race

Clinicians

  • Oncologists who are at least of designation of associate consultant and above in NCCS

Exclusion Criteria:

Patient Participants

  • Disoriented and thus not able to sign informed consent
  • Diagnosed with untreated hearing or visual loss or psychiatric illness
  • Active suicidal ideation

Clinicians

  • Overseas/not practising in Singapore for a significant amount of time

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Investigación de servicios de salud
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Único

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: CCC Intervention Arm

Each participant will be assigned a CCC and receive 6 CCC sessions over the course of 3 months.

CCC sessions will be on exploring participant's illness journey thus far, their concerns, values and priorities.

Sin intervención: Usual Care Arm

Each participant will continue to be followed by the oncologist and receive usual care but will not receive CCC intervention.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Communication Quality
Periodo de tiempo: Baseline, Week 6 after Baseline, and 3 months Post Enrolment.

Feeling Heard and Understood Survey (FHU) is a validated 4-item scale that has been used in palliative care to measure effectiveness of the SIC conversations and the value of the therapeutic relationship between the care team and the patient. The lowest possible score is 0 and the highest possible score is 16, with a higher score indicating that the care team listens well, respects patient's needs, and provides clear communication.

Baseline, Week 6 after Baseline, and 3 months Post Enrolment.
Quality of Life per FACT-G7
Periodo de tiempo: Baseline, Week 6 after Baseline, and 3 months Post Enrolment.

Functional Assessment of Cancer Therapy-General-7 Item version (FACT-G7) is a 7-item questionnaire designed to quickly and effectively capture the most relevant issues to cancer. FACT-G7 scores could potentially range from 0-28, with a higher score indicating a better quality of life.

Baseline, Week 6 after Baseline, and 3 months Post Enrolment.
Health Utility
Periodo de tiempo: Baseline, Week 6 after Baseline, and 3 months Post Enrolment.

EuroQOL Group 5-Dimension (EQ-5D-5L) contains a 5-item descriptive system measuring 5 dimensions: mobility, self-care, usual activities, pain/ discomfort, anxiety/ depression; a visual analogue scale (VAS) measuring overall health status. EQ-5D Index Value (Utility Score) ranges from 0 to 1.0 with higher value indicating better health-related quality of life. The VAS ranges from 0 to 100, with higher scores reflecting better self-rated health.

Baseline, Week 6 after Baseline, and 3 months Post Enrolment.
Spiritual Well-Being
Periodo de tiempo: Baseline, Week 6 after Baseline, and 3 months Post Enrolment.

Functional Assessment of Chronic Illness Therapy - Spiritual Well-Being 12 Item Scale (FACIT-Sp-12) is a validated 12-item survey that is commonly used in the palliative care setting. It has 3 subscales (meaning, peace and faith). Scores in each subscale can potentially range from 0-16 and the total scores can range from 0-48. A higher score indicates greater spiritual well-being, better ability to find purpose in life and drawing comfort from spiritual resources.

Baseline, Week 6 after Baseline, and 3 months Post Enrolment.
Healthcare Utilization - Rate of Unplanned Acute Hospital Utilization
Periodo de tiempo: From Study Enrolment to 3 months Post Enrolment.

The rate of unplanned acute hospital utilization through the emergency department during the study will be collected.

From Study Enrolment to 3 months Post Enrolment.
Healthcare utilization - Length of hospital stay
Periodo de tiempo: From Study Enrolment until Date of Death, up to 3 years.

Data on the length of stay in hospital (bed days) will be collected.

From Study Enrolment until Date of Death, up to 3 years.
Healthcare utilization - Hospital Bill
Periodo de tiempo: From Study Enrolment until Date of Death, up to 3 years.

Data on hospital bill size will be collected.

From Study Enrolment until Date of Death, up to 3 years.
Healthcare utilization - Type of oncological treatment
Periodo de tiempo: From 3 months prior to study enrolment until 3 months after study enrolment.

Data on the type of oncological treatment used will be collected.

From 3 months prior to study enrolment until 3 months after study enrolment.
Healthcare utilization - Chemotherapy usage (line)
Periodo de tiempo: From Study Enrolment until Date of Death, up to 3 years.

Data on the line of chemotherapy (first, second or third or subsequent (fourth and onwards)) will be collected.

From Study Enrolment until Date of Death, up to 3 years.
Healthcare utilization - Intensive care unit visit
Periodo de tiempo: From Study Enrolment until Date of Death, up to 3 years.

Data on the number of intensive care unit visits will be collected.

From Study Enrolment until Date of Death, up to 3 years.
Healthcare utilization - Length of intensive care unit visit
Periodo de tiempo: From Study Enrolment until Date of Death, up to 3 years.

Data on the length of intensive care unit visits will be collected.

From Study Enrolment until Date of Death, up to 3 years.
Healthcare utilization - High dependency unit visit
Periodo de tiempo: From Study Enrolment until Date of Death, up to 3 years.

Data on the number of high dependency unit visits will be collected.

From Study Enrolment until Date of Death, up to 3 years.
Healthcare utilization - Length of high dependency unit visit
Periodo de tiempo: From Study Enrolment until Date of Death, up to 3 years.

Data on the length of high dependency unit visits will be collected.

From Study Enrolment until Date of Death, up to 3 years.
Healthcare utilization - Location of death
Periodo de tiempo: From Study Enrolment until Date of Death, up to 3 years.

Data on the location of death will be collected.

From Study Enrolment until Date of Death, up to 3 years.

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Acceptability - Satisfaction
Periodo de tiempo: 3 months Post Enrolment.

Client satisfaction survey is a 4-item, 4-point scale survey in which patients provide ratings on their satisfaction with the intervention, and their views on its relevance, timeliness, and impact. It has been validated in research studies in the outpatient setting around mental health support. Score can range from 4-16, with a higher score indicating greater client satisfaction.

3 months Post Enrolment.
Feasibility - Approach-to-Enrolment Rates
Periodo de tiempo: From Commencement of Study Recruitment till the End of Recruitment, up to 24 months.

Approach-to-enrolment rates - where feasibility is defined that at least 60% of those patients approached could be enrolled into the study.

From Commencement of Study Recruitment till the End of Recruitment, up to 24 months.
Feasibility - Patient Retention Rate
Periodo de tiempo: Baseline through Study Completion, estimated as up to 3 years.

Patient retention rate - where feasibility is defined that at least 80% of enrolled patients will be able to participate in the study for the planned study duration (3 months).

Baseline through Study Completion, estimated as up to 3 years.
Effectiveness - SIC and ACP documentation
Periodo de tiempo: From Commencement of Study Enrollment through Study Completion, estimated as up to 3 years

The number of SIC and ACP documentation per clinician per enrolled patient during the study duration will be tracked during the intervention period(s) and during the control period(s). Clinical notes will also be read to evaluate if there was relevant documentation by clinician on SIC related issues.

From Commencement of Study Enrollment through Study Completion, estimated as up to 3 years
Effectiveness - Time spent
Periodo de tiempo: From Commencement of Study Enrollment through Study Completion, estimated as up to 3 years

Time spent by CCC in this model and estimated time spent by clinicians on SICs will be collected.

From Commencement of Study Enrollment through Study Completion, estimated as up to 3 years
Acceptability - Clinician experience
Periodo de tiempo: At end of intervention period (28th month).

Clinicians will be surveyed using a modified version of the Clinician Experience Survey (CES). The original CES was developed by Ariadne Labs for the purposes of assessing clinicians perceived feasibility and barriers in engaging patients in SIC. The researchers will modify the CES to form a 4-item scale (score range 4-16), with a higher score indicating greater clinicians' satisfaction with the CCC intervention.

At end of intervention period (28th month).

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Silla de estudio: Shirlyn NEO Hui Shan, MD, PhD, National Cancer Centre, Singapore

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Publicaciones Generales

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

5 de noviembre de 2026

Finalización primaria (Estimado)

30 de junio de 2028

Finalización del estudio (Estimado)

30 de junio de 2029

Fechas de registro del estudio

Enviado por primera vez

21 de julio de 2026

Primero enviado que cumplió con los criterios de control de calidad

24 de julio de 2026

Publicado por primera vez (Actual)

29 de julio de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

10 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

5 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Términos MeSH relevantes adicionales

Otros números de identificación del estudio

  • 2026-1239

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir